Molecular Changes in Circulating microRNAs’ Expression and Oxidative Stress in Adults with Mild Cognitive Impairment: A Biochemical and Molecular Study

References

• Jiang T, Yu JT, Tan L. Novel disease-modifying therapies for Alzheimer’s disease. J Alzheimers Dis. 2012;31:475–492. doi:10.3233/JAD-2012-12064022669013
   PubMed Web of Science ®Google Scholar
• Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L. Mild cognitive impairment: a concept in evolution. J Intern Med. 2014;275:214–228. doi:10.1111/joim.1219024605806
   PubMed Web of Science ®Google Scholar
• Grundman M, Petersen RC, Ferris SH, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004;61:59–66. doi:10.1001/archneur.61.1.5914732621
   PubMed Web of Science ®Google Scholar
• Serrano CM, Dillon C, Leis A, Taragano FE, Allegri RF. Mild cognitive impairment: risk of dementia accord ing to subtypes. Actas Esp Psiquiatr. 2013;41:330–339.24203505
   PubMed Web of Science ®Google Scholar
• Manly JJ, Tang MX, Schupf N, Stern Y, Vonsattel JP, Mayeux R. Frequency and course of mild cognitive impairment in a multiethnic community. Ann Neurol. 2008;63:494–506. doi:10.1002/ana.2132618300306
   PubMed Web of Science ®Google Scholar
• Plassman BL, Langa KM, Fisher GG, et al. Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med. 2008;148:427–434. doi:10.7326/0003-4819-148-6-200803180-0000518347351
   PubMed Web of Science ®Google Scholar
• Tervo S, Kivipelto M, Hanninen T, et al. Incidence and risk factors for mild cognitive impairment: a population-based three-year follow-up study of cognitively healthy elderly subjects. Dement Geriatr Cogn Disord. 2004;17:196–203. doi:10.1159/00007635614739544
   PubMed Web of Science ®Google Scholar
• Petersen RC, Roberts RO, Knopman DS, et al. Mild cognitive impairment: ten years later. Arch Neurol. 2009;66:1447–1455.20008648
   PubMed Web of Science ®Google Scholar
• Tighe SK, OishiK, Mori S, et al. Diffusion tensor imaging of neuropsychiatric symptoms in mild cognitive impairment and Alzheimer’s dementia. J Neuropsychiatry Clin Neurosci. 2012;24:484–488. doi:10.1176/appi.neuropsych.1112037523224456
   PubMed Web of Science ®Google Scholar
• Amlien IK, Fjell AM, Walhovd KB, et al. Mild cognitive impairment: cerebrospinal fluid tau biomarker pathologic levels and longitudinal changes in white matter integrity. Radiology. 2013;266:295–303. doi:10.1148/radiol.1212031923151827
   PubMed Web of Science ®Google Scholar
• Zheng T, Qin L, Chen B, et al. Association of plasma DPP4 activity with mild cognitive impairment in elderly patients with type 2 diabetes: results from the GDMD study in China. Diabetes Care. 2016;39:1594–1601. doi:10.2337/dc16-031627371673
   PubMed Web of Science ®Google Scholar
• Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Rev Neurosci. 2001;24:677–736. doi:10.1146/annurev.neuro.24.1.677
   Web of Science ®Google Scholar
• Qin XY, Cao C, Cawley NX, et al. Decreased peripheral brain-derived neurotrophic factor levels in Alzheimer’s disease: a meta-analysis study (N=7277). Mol Psychiatry. 2017;22:312–320. doi:10.1038/mp.2016.6227113997
   PubMed Web of Science ®Google Scholar
• Krabbe KS, Nielsen AR, Krogh-Madsen R, et al. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia. 2007;50:431–438. doi:10.1007/s00125-006-0537-417151862
   PubMed Web of Science ®Google Scholar
• Herskovits AZ, Guarente L. SIRT1 in neurodevelopment and brain senescence. Neuron. 2014;81:471–483. doi:10.1016/j.neuron.2014.01.02824507186
   PubMed Web of Science ®Google Scholar
• Tapia-Arancibia L, Aliaga E, Silhol M, Arancibia S. New insights into brain BDNF function in normal aging and Alzheimer disease. Brain Res Rev. 2008;59:201–220. doi:10.1016/j.brainresrev.2008.07.00718708092
   PubMed Web of Science ®Google Scholar
• Nagata T, Shinagawa S, Nukariya K, Yamada H, Nakayama K. Association between BDNF polymorphism (Val66Met) and executive function in patients with amnestic mild cognitive impairment or mild Alzheimer disease. Dement Geriatr Cogn Disord. 2012;33(266–272):684. doi:10.1159/000339358
   Web of Science ®Google Scholar
• Bonda DJ, Lee HG, Camins A, et al. The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considera tions. Lancet Neurol. 2011;10:275–279. doi:10.1016/S1474-4422(11)70013-821349442
   PubMed Web of Science ®Google Scholar
• Ishibashi Y, Matsui T, Maeda S, Higashimoto Y, Yamagishi S. Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc Diabetol. 2013;12:125. doi:10.1186/1475-2840-12-12523984879
   PubMed Web of Science ®Google Scholar
• Wu A, Ying Z, Gomez-Pinilla F. The interplay between oxidative stress and brain-derived neurotrophic factor modulates the outcome of a saturated fat diet on synaptic plasticity and cognition. Eur J Neurosci. 2004;19:1699–1707. doi:10.1111/j.1460-9568.2004.03246.x15078544
   PubMed Web of Science ®Google Scholar
• Zheng TP, Yang F, Gao Y, et al. Increased plasma DPP4 activities predict new-onset atherosclerosis in association with its proinflammatory effects in Chinese over a four year period: a prospective study. Atherosclerosis. 2014;235:619–624. doi:10.1016/j.atherosclerosis.2014.05.95624968315
   PubMed Web of Science ®Google Scholar
• Baierle M, Nascimento SN, Moro AM, et al. Relationship between inflammation and oxidative stress and cognitive decline in the institutionalized elderly. Oxid Med Cell Longev. 2015;2015:804198. doi:10.1155/2015/80419825874023
   PubMed Web of Science ®Google Scholar
• Gaman AM, Uzoni A, Popa-Wagner A, Andrei A, Petcu EB. The role of oxidative stress in etiopathogenesis of chemotherapy induced cognitive Impairment (CICI)-”Chemobrain”. Aging Dis. 2016;7(3):307–317. doi:10.14336/AD.2015.102227330845
   PubMed Web of Science ®Google Scholar
• Hermann DM, Doeppner TR, Popa-Wagner A. Opportunities and limitations of vascular risk factor models in studying plasticity-promoting and restorative ischemic stroke therapies. Neural Plast. 2019;Nov(2019):9785476.
   Google Scholar
• Zagrean AM, Hermann DM, Opris I, Zagrean L, Popa-Wagner A. Multicellular crosstalk between exosomes and the neurovascular unit after cerebral ischemia. Therapeutic Implications Front Neurosci. 2018;6(12):811.
   Google Scholar
• AGriñan-Ferré C, Corpas R, Puigoriol-Illamola D, Palomera-Avalos V, Sanfeliu C, Pallàs M. Understanding epigenetics in the neurodegeneration of alzheimer’s disease: SAMP8 mouse model. J Alzheimers Dis. 2018;62:943–963. doi:10.3233/JAD-17066429562529
   PubMed Web of Science ®Google Scholar
• Chung HY, Kim DH, Lee EK, et al. Redefining chronic inflammation in aging and age-related diseases: proposal of the senoinflammation concept. Aging Dis. 2019;10:367–382. doi:10.14336/AD.2018.032431011483
   PubMed Web of Science ®Google Scholar
• Petersen KS, Smith C. Ageing-associated oxidative stress and inflammation are alleviated by products from grapes. Oxidative Med Cell Longev. 2016;2016:1–12. doi:10.1155/2016/6236309
   Web of Science ®Google Scholar
• Escobar KA, Cole NH, Mermier CM, VanDusseldorp TA. Autophagy and aging: maintaining the proteome through exercise and caloric restriction. Aging Cell. 2019;18.
   Web of Science ®Google Scholar
• Pourmemar E, Majdi A, Haramshahi M, Talebi M, Karimi P, Sadigh-Eteghad S. Intranasal cerebrolysin attenuates learning and memory impairments in D-galactose-induced senescence in mice. Exp Gerontol. 2017;87:16–22. doi:10.1016/j.exger.2016.11.01127894939
   PubMed Web of Science ®Google Scholar
• Yu Y, Feng L, Li J, et al. The alteration of autophagy and apoptosis in the hippocampus of rats with natural aging-dependent cognitive deficits. Behav Brain Res. 2017;334:155–162. doi:10.1016/j.bbr.2017.07.00328688896
   PubMed Web of Science ®Google Scholar
• Xie B, Zhou H, Zhang R, et al. Serum miR-206 and miR-132 as potential circulating biomarkers for mild cognitive impairment. J Alzheimers Dis. 2015;45(3):721–731. doi:10.3233/JAD-14284725589731
   PubMed Web of Science ®Google Scholar
• Muller M, Kuiperij HB, Versleijen AA, et al. Validation of microRNAs in cerebrospinal fluid as biomarkers for different forms of dementia in a multicenter study. J Alzheimers Dis. 2016;52:1321–1333. doi:10.3233/JAD-16003827104900
   PubMed Web of Science ®Google Scholar
• Najaraj S, Laskowska-Kaszub K, Dębski KJ, et al. Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer’s disease patients from non-demented subjects. Oncotarget. 2017;8:16122–16143. doi:10.18632/oncotarget.1510928179587
   PubMedGoogle Scholar
• Martinez B, Peplow PV. MicroRNAs as diagnostic and therapeutic tools for Alzheimer’s disease: advances and limitations. Neural Regen Res. 2019;14(2):242–255. doi:10.4103/1673-5374.24478430531004
   PubMed Web of Science ®Google Scholar
• Miya Shaik M, Tamargo IA, Abubakar MB, Kamal MA, Greig NH, Gan SH. The role of microRNAs in Alzheimer’s Disease and their therapeutic potentials. Genes (Basel). 2018;9(4):174. doi:10.3390/genes9040174
   Web of Science ®Google Scholar
• Melo CA, Melo SA. Biogenesis and physiology of microRNAs In: Fabbri M, editor. Non-Coding RNAs and Cancer. NewYork, NY, USA: Springer; 2014:5–24.
   Google Scholar
• Deng S, Wang H, Jia C, et al. MicroRNA-146a induces lineage-negative bone marrow cell apoptosis and senescence by targeting polo-like kinase 2 expression. Arterioscler Thromb Vasc Biol. 2017;37:280–290. doi:10.1161/atvbaha.116.30837827908889
   PubMed Web of Science ®Google Scholar
• Ansari A, Maffioletti E, Milanesi E, et al. miR-146a and miR-181a are involved in the progression of mild cognitive impairment to Alzheimer’s disease. Neurobiol Aging. 2019;82:102–109. doi:10.1016/j.neurobiolaging.2019.06.00531437718
   PubMed Web of Science ®Google Scholar
• Petersen RC, Roberts RO, Knopman DS, et al. Mild cognitive impairment: ten years later. Arch Neurol. 2009;66(599):1447–1455.20008648
   PubMedGoogle Scholar
• Sullivan K. Estimates of interrater reliability for the Logical Memory subtest of the Wechsler Memory Scale- Revised. J Clin Exp Neuropsychol. 1996;18:707–712. doi:10.1080/016886396084082938941855
   PubMed Web of Science ®Google Scholar
• Liu DH, Zhang XQ, Chen B, et al. Neurophysiologic tests to distinguish MCI and mildAD. J Brain Nerv Dis. 2008;16:223–226.
   Google Scholar
• Dai XY, Ryan JJ, Paolo AM, Harrington RG. Factor analysis of the mainland Chinese version of the Wechsler Adult Intelligence Scale (WAIS-RC) in a brain-damaged sample. Int J Neurosci. 1990;55:107–111. doi:10.3109/002074590089859562084035
   PubMed Web of Science ®Google Scholar
• Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. THE Index of ADL: a standardized measure of biological and psychosocial function. JAMA. 1963;185:914–919.14044222
   PubMed Web of Science ®Google Scholar
• Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695–699. doi:10.1111/j.1532-5415.2005.53221.x15817019
   PubMed Web of Science ®Google Scholar
• Folstein MF, Folstein SE, McHugh PR. Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198.1202204
   PubMed Web of Science ®Google Scholar
• Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303–308. doi:10.1001/archneur.56.3.30310190820
   PubMed Web of Science ®Google Scholar
• Porteri C, Frisoni GB. Biomarker-based diagnosis of mild cognitive impairment due to Alzheimer’s disease: how and what to tell. A kickstart to an ethical discussion. Front Aging Neurosci. 2014;6:41. doi:10.3389/fnagi.2014.0004124678299
   PubMed Web of Science ®Google Scholar
• Godfrey M. Majid DSA: renal handling of circulating nitrates in anesthetized dogs. Am J Physiol Renal Physiol. 1998;275(1):F68–F73. doi:10.1152/ajprenal.1998.275.1.F68
   Web of Science ®Google Scholar
• Tarpey MM, Fridovich I. Methods of detection of vascular reactive species: nitric oxide, super oxide, hydrogen peroxide, and peroxy nitrate. Circ Res. 2001;89:236–244. doi:10.1161/hh1501.094365
   Web of Science ®Google Scholar
• Sravani PV, Babu NK, Gopal KV, et al. Determination of oxidative stress in vitiligo by measuring superoxide dismutase and catalase levels in vitiliginous and non-vitiliginous skin. Indian J Dermatol Venereol Leprol. 2009;3:268–271.
   Google Scholar
• Goth L. A simple method for determination of serum catalase activity and revision of reference range. Clin Chim Acta. 1991;196:143–152. doi:10.1016/0009-8981(91)90067-M2029780
   PubMed Web of Science ®Google Scholar
• Aebi H. Catalase in vitro. Meth Enzymol. 1984;105:121–126.
   PubMed Web of Science ®Google Scholar
• Gabr SA, Al-Ghadir AH. Role of cellular oxidative stress and cytochrome c in the pathogenesis of psoriasis. Arch Dermatol Res. 2012;304(6):451–457. doi:10.1007/s00403-012-1230-822421888
   PubMed Web of Science ®Google Scholar
• Gabr SA, Alghadir AH. Prediction of fibrosis in hepatitis C patients: assessment using hydroxyproline and oxidative stress biomarkers. Virusdisease. 2014;25(1):91–100. doi:10.1007/s13337-013-0182-824426315
   PubMedGoogle Scholar
• Zheng T, Gao Y, Baskota A, Chen T, Ran X, Tian H. Increased plasma DPP4 activity is predictive of prediabetes and type 2 diabetes onset in Chinese over a four-year period: result from the China National Diabetes and metabolic disorders study. J Clin Endocrinol Metab. 2014;99:E2330–334. doi:10.1210/jc.2014-148025029421
   PubMed Web of Science ®Google Scholar
• Zheng T, Chen T, Liu Y, Gao Y, Tian H. Increased plasma DPP4 activity predicts new-onset hypertension in Chinese over a 4-year period: possible associations with inflammation and oxidative stress. J Hum Hypertens. 2015;29:424–429. doi:10.1038/jhh.2014.11125411054
   PubMed Web of Science ®Google Scholar
• Al-Rawaf HA, Alghadir AH, Gabr SA. MicroRNAs as biomarkers of pain intensity in patients with chronic fatigue syndrome. Pain Pract. 2019;19(8):848–860. doi:10.1111/papr.1281731282597
   PubMed Web of Science ®Google Scholar
• Safari F, Hosseini H, Bayat M, Ranjbar A. Synthesis and evaluation of antimicrobial activity, cytotoxic and proapoptotic effects of novel spiro-4H-pyran derivatives. RSC Adv. 2019;9(43):24843–24851. doi:10.1039/C9RA03196K
   PubMed Web of Science ®Google Scholar
• Bermejo P, Martin-Arag´on S, Benedi J, et al. Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer’s disease from mild cognitive impairment. FreeRadic Res. 2008;42:162–170.
   Google Scholar
• Markesbery WR, Lovell MA. DNA oxidation in Alzheimer's disease. Antioxidants Redox Signal. 2006;8:2039–2045. doi:10.1089/ars.2006.8.2039
   PubMed Web of Science ®Google Scholar
• Nunomura A, Honda K, Takeda A, Hirai K, Zhu X, SmithMA PG. Oxidative damage to RNA in neurodegenerative diseases. J Biomed Biotechnol. 2006;(2006):1–6. doi:10.1155/JBB/2006/82323
   Google Scholar
• Delibas N, Ozcankaya R, Altuntas I. Clinical importance of erythrocyte malondialdehyde levels as a marker for cognitive deterioration in patients with dementia of Alzheimer type: a repeated study in 5-year interval. Clin Biochem. 2002;32:137–141. doi:10.1016/S0009-9120(02)00287-4
   Web of Science ®Google Scholar
• Keller JN, Schmitt FA, Scheff SW, et al. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology. 2005;64:1152–1156. doi:10.1212/01.WNL.0000156156.13641.BA15824339
   PubMed Web of Science ®Google Scholar
• Popa-Wagner A, Mitran S, Sivanesan S, Chang E, Buga AM. ROS and brain diseases: the good, the bad, and the ugly. Oxid Med Cell Longev. 2013;2013:963520. doi:10.1155/2013/96352024381719
   PubMed Web of Science ®Google Scholar
• Jellinger KA. Pathology and pathogenesis of vascular cognitive impairment-a critical update. Front Aging Neurosci. 2013;5:17. doi:10.3389/fnagi.2013.0001723596414
   PubMed Web of Science ®Google Scholar
• Cervellati C, Cremonini E, Bosi C, et al. Systemic oxidative stress in older patients with mild cognitive impairment or late onset Alzheimer’s disease. Curr Alzheimer Res. 2013;10(4):365–372. doi:10.2174/156720501131004000322950912
   PubMed Web of Science ®Google Scholar
• Wei G, Dawson VL, Zweier JL. Role of neuronal and endothelial nitric oxide synthase in nitric oxide generation in the brain following cerebral ischemia. Biochimica et Biophysica Acta. 1999;1455:23–24. doi:10.1016/S0925-4439(99)00051-4
   Web of Science ®Google Scholar
• Milstien S, Sakai N, Brew BJ, et al. Cerebrospinal fluid nitrite/nitrate levels in neurological diseases. J Neuro Chem. 1994;63(3):1178–1180. doi:10.1046/j.1471-4159.1994.63031178.x
   Web of Science ®Google Scholar
• Moncada S, Higgs EA. The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol. 2006;147(suppl1):S193–201. doi:10.1038/sj.bjp.070645816402104
   PubMed Web of Science ®Google Scholar
• Boje KM, Arora PK. Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death. Brain Res. 1992;587:250–256. doi:10.1016/0006-8993(92)91004-X1381982
   PubMed Web of Science ®Google Scholar
• Moro MA, Darley-Usmar VM, Goodwin DA, et al. Paradoxical fate and biological action of peroxynitrite on human platelets. Proc Natl Acad Sci USA. 1994;91:6702–6706. doi:10.1073/pnas.91.14.67027517561
   PubMed Web of Science ®Google Scholar
• Rogers J, Luber-Narod J, Styren S, Civin WH. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer’s disease. Neurobiol Aging. 1988;9(4):339–349. doi:10.1016/S0197-4580(88)80079-43263583
   PubMed Web of Science ®Google Scholar
• Lee YJ, Han SB, Nam SY, Oh KW, Hong JT. Inflammation and Alzheimer’s disease. Arch Pharm Res. 2010;33:1539–1556.21052932
   PubMed Web of Science ®Google Scholar
• Marcus DL, Thomas C, Rodriguez C, et al. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer’s disease. Exp Neurol. 1998;150:40–44. doi:10.1006/exnr.1997.67509514828
   PubMed Web of Science ®Google Scholar
• Omar RA, Chyan YJ, Andorn AC, Poeggeler B, Robakis NK, Pappolla MA. Increased expression but reduced activity of antioxidant enzymes in Alzheimer’s disease. J Alzheimers Dis. 1999;1:139–145. doi:10.3233/JAD-1999-130112213999
   PubMedGoogle Scholar
• Ortiz GG, Pacheco Mois´es FP, Mireles-Ram´ırez M, et al. Oxidative stress: love and hate history in central nervous system. Adv Protein Chem Struct Biol. 2017;108:1–31.28427557
   PubMed Web of Science ®Google Scholar
• Revel F, Gilbert T, Roche S, et al. Influence of oxidative stress biomarkers on cognitive decline. J Alzheimers Dis. 2015;45:553–560. doi:10.3233/JAD-14179725589716
   PubMed Web of Science ®Google Scholar
• Irizarry MC, Raman R, Schwarzschild MA, et al. Plasma urate and progression of mild cognitive impairment. Neurodegener Dis. 2009;6:23–28. doi:10.1159/00017088319066433
   PubMed Web of Science ®Google Scholar
• Aquilano K, Baldelli S, Ciriolo MR. Glutathione: new roles in redox signaling for an old antioxidant. Front Pharmacol. 2014;5:196. doi:10.3389/fphar.2014.0019625206336
   PubMed Web of Science ®Google Scholar
• Nicotera P. Caspase requirement for neuronal apoptosis and neurodegeneration. IUBMB Life. 2000;49:421–425. doi:10.1080/15216540041027210902574
   PubMed Web of Science ®Google Scholar
• Porter AG, Janicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999;6:99–104. doi:10.1038/sj.cdd.440047610200555
   PubMed Web of Science ®Google Scholar
• Shah AJ, Epport K, Azen, et al. Progressive declines in neurocognitive function among survivors of hematopoietic stem cell transplantation for pediatric hematologic malignancies. J Ped Hematol Oncol. 2008;30:411–418. doi:10.1097/MPH.0b013e318168e750
   Web of Science ®Google Scholar
• D’Amelio M, Sheng M, Cecconi F. Caspase-3 in the central nervous system: beyond apoptosis. Trends Neurosci. 2012;35:700–709. doi:10.1016/j.tins.2012.06.00422796265
   PubMed Web of Science ®Google Scholar
• Robertson GS, Crocker SJ, Nicholson DW, Schulz JB. Neuroprotection by the inhibition of apoptosis. Brain Pathol. 2000;10:283–292. doi:10.1111/j.1750-3639.2000.tb00262.x10764048
   PubMed Web of Science ®Google Scholar
• Eichenbaum H. Hippocampus: cognitive processes and neural representations that underlie declarative memory. Neuron. 2004;44:109–120. doi:10.1016/j.neuron.2004.08.02815450164
   PubMed Web of Science ®Google Scholar
• Liang HW, Qiu SF, Shen J, et al. Genistein attenuates oxidative stress and neuronal damage following transient global cerebral ischemia in rat hippocampus. Neurosci Lett. 2008;438:116–120. doi:10.1016/j.neulet.2008.04.05818467029
   PubMed Web of Science ®Google Scholar
• Rodriguez-Martinez E, Martinez F, Espinosa-Garcia MT, Maldonado P, Rivas-Arancibia S. Mitochondrial dysfunction in the hippocampus of rats caused by chronic oxidative stress. Neuroscience. 2013;252:384–395. doi:10.1016/j.neuroscience.2013.08.01823988432
   PubMed Web of Science ®Google Scholar
• Aisen PS. Serumbrain-derived neurotrophic factor and the risk for dementia. JAMA. 2014;311:1684–1685. doi:10.1001/jama.2014.312024756518
   PubMed Web of Science ®Google Scholar
• Gezen-Ak D, Dursun E, Hanagasi H, et al. BDNF, TNFalpha, HSP90, CFH, and IL-10 serum levels in patients with early or late onset Alzheimer’sdisease or mild cognitive impairment. J Alzheimers Dis. 2013;37:185–195. doi:10.3233/JAD-13049723948885
   PubMed Web of Science ®Google Scholar
• Laske C, Stellos K, Hoffmann N, et al. Higher BDNF serum levels predict slower cognitive decline in Alzheimer’s disease patients. Int J Neuropsychopharmacol. 2011;14:399–404. doi:10.1017/S146114571000100820860877
   PubMed Web of Science ®Google Scholar
• Faria MC, Gonc¸alves GS, Rocha NP, et al. Increased plasma levels of BDNF and inflammatory markers in Alzheimer’sdisease. J Psychiatr Res. 2014;53:166–172. doi:10.1016/j.jpsychires.2014.01.01924576746
   PubMed Web of Science ®Google Scholar
• Jeong H, et al. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med. 2011;18:159–165. doi:10.1038/nm.255922179316
   PubMed Web of Science ®Google Scholar
• Zhang C, et al. Hormetic effect of panaxatriol saponins confers neuroprotection in PC12 cells and zebrafish through PI3K/AKT/mTOR and AMPK/SIRT1/FOXO3pathways. Sci Rep. 2017;7:41082. doi:10.1038/srep4108228112228
   PubMed Web of Science ®Google Scholar
• Chen B, Zheng T, Qin L, et al. Strong association between plasma dipeptidyl peptidase-4 activity and impaired cognitive function in elderly population with normal glucose tolerance. Front Aging Neurosci. 2017;9:247. doi:10.3389/fnagi.2017.0024728798686
   PubMed Web of Science ®Google Scholar
• Zheng T, Baskota A, Gao Y, Chen T, Tian H, Yang F. Increased plasma DPP4 activities predict new-onset hyperglycemia in Chinese over a four year period: possible associations with inflammation. Metabolism. 2015;64:498–505. doi:10.1016/j.metabol.2014.12.00425592717
   PubMed Web of Science ®Google Scholar
• Zheng T, Liu H, Qin L, et al. Oxidative stress-mediated influence of plasma DPP4 activity to BDNF ratio on mild cognitive impairment in elderly type 2 diabetic patients: results from the GDMD study in China. Metabolism. 2018b;87:105–112. doi:10.1016/j.metabol.2018.03.01429572131
   PubMed Web of Science ®Google Scholar
• Biessels GJ, Strachan MW, Visseren FL, Kappelle LJ, Whitmer RA. Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions. Lancet Diabetes Endocrinol. 2014;2:246–255. doi:10.1016/S2213-8587(13)70088-324622755
   PubMed Web of Science ®Google Scholar
• Swomley AM, Butterfield DA. Oxidative stress in Alzheimer disease and mild cognitive impairment: evidence from human data provided by redox proteomics. Arch Toxicol. 2015;89:1669–1680. doi:10.1007/s00204-015-1556-z26126631
   PubMed Web of Science ®Google Scholar
• Zheng T, Qin L, Chen B, et al. Association of plasma dpp4 activity with mild cognitive impairment in elderly patients with type 2 diabetes: results from the GDMD study in China. Diabetes Care. 2016b;39:1594–1601.27371673
   PubMed Web of Science ®Google Scholar
• Im HI, Kenny PJ. MicroRNAs in neuronal function and dysfunction. Trends Neurosci. 2012;35(5):325–334. doi:10.1016/j.tins.2012.01.00422436491
   PubMed Web of Science ®Google Scholar
• Saba R, Schratt GM. MicroRNAs in neuronal development, function and dysfunction. Brain Res. 2010;1338:3–13. doi:10.1016/j.brainres.2010.03.10720380818
   PubMed Web of Science ®Google Scholar
• Konovalova J, Gerasymchuk D, Parkkinen I, Chmielarz P, Domanskyi A. Interplay between MicroRNAs and oxidative stress in neurodegenerative diseases. Int J Mol Sci. 2019;20(23):6055. doi:10.3390/ijms20236055
   PubMed Web of Science ®Google Scholar
• Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010;11:597–610. doi:10.1038/nrg284320661255
   PubMed Web of Science ®Google Scholar
• Schmiedel JM, Klemm SL, Zheng Y, et al. Gene expression. MicroRNA Control of Protein Expression Noise Science. 2015;348:128–132.25838385
   PubMedGoogle Scholar
• Denk J, Boelmans K, Siegismund C, Lassner D, Arlt S, Jahn H. MicroRNA profiling of CSF reveals potential biomarkers to detect Alzheimer’s disease. PLoS One. 2015;10:e0126423. doi:10.1371/journal.pone.012642325992776
   PubMed Web of Science ®Google Scholar
• Kayano M, Higaki S, Satoh JI, et al. Plasma microRNA biomarker detection for mild cognitive impairment using differential correlation analysis. Biomark Res. 2016;4:22.27999671
   PubMed Web of Science ®Google Scholar
• Lusardi TA, Phillips JI, Wiedrick JT, et al. MicroRNAs in human cerebrospinal fluid as biomarkers for Alzheimer’s disease. J Alzheimers Dis. 2017;55:1223–1233. doi:10.3233/JAD-16083527814298
   PubMed Web of Science ®Google Scholar
• Jia LH, Liu YN. Downregulated serum miR-223 serves as biomarker in Alzheimer’s disease. Cell Biochem Funct. 2016;34:233–237. doi:10.1002/cbf.318427027823
   PubMed Web of Science ®Google Scholar
• Hong H, Li Y, Su B. Identification of circulating miR-125b as a potential biomarker of Alzheimer’s Disease in APP/PS1 transgenic mouse. J Alzheimers Dis. 2017;59(4):1449–1458. doi:10.3233/JAD-17015628731435
   PubMed Web of Science ®Google Scholar
• Tan L, Yu JT, Liu QY, et al. Circulating miR-125b as a biomarker of Alzheimer’s disease. J Neurol Sci. 2014;336(1–2):52–56. doi:10.1016/j.jns.2013.10.00224139697
   PubMed Web of Science ®Google Scholar
• Guan B, Li Q, Shen L, et al. and Li XH: microRNA-205 directly targets Krüppel-like factor 12 and is involved in invasion and apoptosis in basal-like breast carcinoma. Int J Oncol. 2016;49:720–734. doi:10.3892/ijo.2016.357327278159
   PubMed Web of Science ®Google Scholar
• Jiang M, Xiang Y, Wang D, et al. Dysregulated expression of miR-146a contributes to age-related dysfunction of macrophages. Aging Cell. 2012;11:29–40. doi:10.1111/j.1474-9726.2011.00757.x21981419
   PubMed Web of Science ®Google Scholar
• Keller A, Backes C, Haas J, et al. disease micro RNAs using next-generation sequencing. Alzheimers Dement. 2016;12:565–576. doi:10.1016/j.jalz.2015.12.01226806387
   PubMed Web of Science ®Google Scholar
• Wu Y, Xu J, Xu J, et al. Lower serum levels of miR-29c-3p and miR-19b-3p as biomarkers for Alzheimer’s disease. Tohoku J Exp Med. 2017;242:129–136. doi:10.1620/tjem.242.12928626163
   PubMed Web of Science ®Google Scholar
• Perluigi M, Barone E, Di Domenico F, Butterfield DA. Aberrant protein phosphorylation in Alzheimer disease brain disturbs pro-survival and cell death pathways. Biochim Biophys Acta. 2016;1862:1871–1882. doi:10.1016/j.bbadis.2016.07.00527425034
   PubMed Web of Science ®Google Scholar
• Le MT, Teh C, Shyh-Chang N, et al. MicroRNA-125b is a novel negative regulator of p53. Genes Dev. 2009;23:862–876. doi:10.1101/gad.176760919293287
   PubMed Web of Science ®Google Scholar
• Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol. 2007;8:275–283. doi:10.1038/nrm214717380161
   PubMed Web of Science ®Google Scholar
• Ma X, Liu L, Meng J. MicroRNA-125b promotes neurons cell apoptosis and Tau phosphorylation in Alzheimer’s disease. Neurosci Lett. 2017;661:57–62. doi:10.1016/j.neulet.2017.09.04328947385
   PubMed Web of Science ®Google Scholar
• Krek A, Grun D, Poy MN, et al. Combinatorial microRNA target predictions. Nat Genet. 2005;37:495–500. doi:10.1038/ng153615806104
   PubMed Web of Science ®Google Scholar
• Prozorovski T, Schulze-Topphoff U, Glumm R, et al. Sirt1 contributes critically to the redox-dependent fate of neural progenitors. Nat Cell Biol. 2008;10:385–394. doi:10.1038/ncb170018344989
   PubMed Web of Science ®Google Scholar
• Im H-I, Kenny PJ. MicroRNAs in neuronal function and dysfunction. Trends Neurosci. 2012;35:325–334. doi:10.1016/j.tins.2012.01.00422436491
   PubMed Web of Science ®Google Scholar
• Strum JC, Johnson JH, Ward J, et al. MicroRNA 132 regulates nutritional stress-induced chemokine production through repression of SirT1. Mol Endocrinol. 2009;23:1876–1884. doi:10.1210/me.2009-011719819989
   PubMedGoogle Scholar
• Lee ST, Chu K, Jung KH, et al. miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model. Ann Neurol. 2012;72:269–277. doi:10.1002/ana.2358822926857
   PubMed Web of Science ®Google Scholar
• Jin Y, Chen Z, Liu X, Zhou X. Evaluating the microRNA targeting sites by luciferase reporter gene assay. Methods Mol Biol. 2013;936:117–127.23007504
   PubMedGoogle Scholar
• Nicolas FE. Experimental validation of microRNA targets using a luciferase reporter system. Methods Mol Biol. 2011;732:139–152.21431711
   PubMedGoogle Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–233. doi:10.1016/j.cell.2009.01.00219167326
   PubMed Web of Science ®Google Scholar
• Dai Y, Zhou X. Computational methods for the identification of microRNA targets. Open AccessBioinform. 2010;2:29–39.
   Google Scholar